Press Release – RepliCel Receives Japanese Patent

Snippet from the press release:

RepliCel Life Sciences Inc. today announced that it has been granted a patent by Japan’s Ministry of International Trade and Industry for hair follicle mesenchymal stem cells and their use thereof. These cells are used in RepliCel’s RCH-01 treatment for androgenetic alopecia, also known as pattern hair loss. With the issuance of this patent, RepliCel now has patents issued in Japan, the United States, Australia and the European Union protecting its technology with other jurisdictions still pending.

This patent approval is an important milestone as RepliCel’s licensing partner, Shiseido Company, prepares to conduct human clinical trials using RCH-01. Shiseido has an exclusive license to use RCH-01 in Japan, China, South Korea, Taiwan and the ASEAN countries representing a population of approximately 2.1 billion people. According to the International Society of Hair Restoration (ISHR), the leading authority on hair loss treatment and restoration, almost one million patients sought treatment for hair loss in 2012. Of this number, 41% of the patients were from Asia, representing the largest single region, surpassing the United States by 15%.

Read the rest — RepliCel Receives Japanese Patent Covering its Hair Regeneration Technology